A Phase 3, Randomized, Double-blind Trial of Pembrolizumab (MK-3475) Plus Enzalutamide Plus ADT Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (KEYNOTE-991)

Project: Research

Project Details

StatusActive
Effective start/end date14/05/2013/05/25

Keywords

  • phase 3 study
  • treatment efficacy
  • prostate cancer
  • clinical trial